logo
Medical news
of the North Caucasus
Scientific journal
Mass media registration certificate dated December 7, 2006.
Series ПИ #ФС 77-26521.
Federal service for surveillance over non-violation of the legislation in the sphere of mass communications and protection of cultural heritage.
ISSN 2073-8137
rus
русский
eng
english

Site search



Correspondence address
310 Mira Street, Stavropol, Russia, 355017

Tel
+7 8652 352524; +7 8652 353229.

Fax
+7 8652 352524.

E-mail
medvestnik@stgmu.ru

Polymorphism of clinical manifestations of cystic fibrosis-related diabetes

[Cystic fibrosis]
Elena Ivanovna Kondratieva; Roza Atanesyan; Elena Alexandrovna Vasilyeva; Elena Alexandrovna Boychenko; Leonid Klimov; Svetlana Dolbnya;

Cystic fibrosis (CF) is one of the most common recessive diseases. High incidence combined with high penetrance of the phenotype and the incidence of life-threatening complications requires further study. The search continues for the causes of the phenotypic diversity of patients with CF, caused not only by various CFTR mutations, but also by the role of genetic and environmental modifiers.

One of the most common complications of CF is diabetes mellitus (DM). Impaired glucose tolerance (IGT) occurs in 50–70 % of adult CF patients, and clinically, diabetes mellitus manifests itself in 5–15 % of cases. The role of carbohydrate metabolism disorders in the prognosis and course of CF is demonstrated. The article discusses the clinical cases of cystic fibrosis-associated diabetes (CFAD) in children, features of its manifestation, course and treatment.

Download

References:
1. Cystic fibrosis foundation annual patient registry 2017. Available at: https://www.cff.org/Research/Researcher-Resources/Patient-Registry/2017-Patient-RegistryAnnual-Data-Report. Accessed April 08, 2019.
2. Moran A., Becker D., Casella S. J. [et al.]. Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes: a technical review. Diabetes Care. 2010;33(12):2677-2683. https://doi.org/10.2337/dc10-1279
3. Register of cystic fibrosis patients in the Russian Federation. 2018 year. Edited by Amelina E. L., Kashirsky N. Yu., Kondratyeva E. I., Krasovsky S. A., Starinova M. A., Voronkova A. Yu. M.: «MEDPRAKTIKA-M», 2020. (In Russ.).
4. Scheuing N., Holl R. W., Dockter G., Fink K., Junge S. [et al.]. Diabetes in cystic fibrosis: multicenter screening results based on current guidelines. PLoS One. 2013;8(12):e81545:1-9. https://doi.org/10.137
5. Yi Y., Norris A. W., Wang K. Abnormal Glucose Tolerance in Infants and Young Children with Cystic Fibrosis. Am. J. Respir. Crit. Care Med. 2016;194(8):924-925. https://doi.org/10.1164/rccm.201608-1579ed
6. Hart N. J., Aramandla R., Poffenberger G. Cystic fibrosis-related diabetes is caused by islet loss and inflammation. JCI Insight. 2018;3(8):e98240. https://doi.org/10.1172/jci.insight.98240
7. Bilodeau C., Bardou O., Maillé É. Deleterious impact of hyperglycemia on cystic fibrosis airway ion transport and epithelial repair. J. Cyst. Fibros. 2016;15(1):43-51. https://doi.org/10.1016/j.jcf.2015.04.002
8. van Meerkerk G., van de Graff E. A., Kwakkel-van Erp J. M. [et al.]. Diabetes before and after lung transplantation in patients with cystic fibrosis and other lung diseases. Diabet Med. 2012;29(8):e159-e162. https://doi.org/10.1111/j.1464-5491.2012.03676.x
9. Colomba J., Boudreau V., Lehoux-Dubois C. The main mechanism associated with progression of glucose intolerance in older patients with cystic fibrosis is insulin resistance and not reduced insulin secretion capacity. J. Cyst. Fibros. 2019;18(4):551-556. https://doi.org/10.1016/j.jcf.2019.01.009
10. Esther C. R., O’Neal W., Polineni D., Mahon A., Isaacman S., Knowles M. A combined ’omics strategy identifies the methionine salvage pathway as a novel therapeutic target for cystic fibrosis airways disease. Am. J. Respir. Crit. Care Med. 2017;195:48-52. https://doi.org/10.1164/rccm.201701-0134OC
11. Colombo C., Alicandro G., Gambazza S. Ventilation inhomogeneity is associated with OGTT-derived insulin secretory defects in cystic fibrosis. Pediatr. Pulmonol. 2019;54(2):141-149. https://doi.org/10.1002/ppul.24212
12. Schmid K., Fink K., Holl R. W. Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test. J. Cyst. Fibros. 2014;13(1):80-85. https://doi.org/10.1016/j.jcf.2013.06.001
13. Samoilenko V. A., Petrova N. V., Babadzhanova G. Yu., Nagorny A. B., Krasovsky S. A., Chuchalin A. G. The role of the TCF7L2 modifier gene in the onset of diabetes in adult patients with cystic fibrosis. Pulmonologiya. – Pulmonology. 2014;2:33-39. (In Russ.). https://doi.org/10.18093/0869-0189-2014-0-2-33-39
14. Zhi-qiu Huang, Yao-qi Liao, Run-ze Huang, Jin-peng Chen, Hui-lin Sun. Possible role of TCF7L2 in the pathogenesis of type 2 diabetes mellitus. Biotechnology & Biotechnological Equipment. 2018;32(4):830-834. https://doi.org/10.1080/13102818.2018.1438211
15. National consensus «Cystic fibrosis: definition, diagnostic criteria, therapy» (Coordinators: Kapranov N., Kondratyeva E., Kashirskaya N.). Meditsinskaya genetika. – Medical Genetics. 2016;11:108-109. (In Russ.).
16. Onady G. M., Stolfi A. Insulin and oral agents for managing cystic fibrosis-related diabetes. Cochrane Database Syst. Rev. 2013;7:1-23. https://doi.org/10.1002/14651858.CD004730.pub3
17. Moran A., Pillay K., Becker D. J., Acerini C. L. Management of cystic fibrosis-related diabetes in children and adolescents. Pediatric Diabetes. 2014;15(20):65-76. https://doi.org/10.1111/pedi.12178
18. Moran A., Brunzell C., Cohen R. C. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care. 2010;33(12):2697-708. https://doi.org/10.2337/dc10-1768
19. Kashirskaya N. Yu. The state of the gastrointestinal tract, pancreas and hepatobiliary system in patients with cystic fibrosis. Abstract. dis. ... Doct. med. sciences. 2001. (In Russ.).
20. Moran A. Is it time to treat CFRD with oral diabetes agents? Lancet Diabetes Endocrinol. 2018;6(2):85-87. https://doi.org/10.1016/S2213-8587

Keywords: genotype, phenotype, cystic fibrosis-related diabetes, life expectancy, insulin therapy


Founders:
Stavropol State Medical Academy
Pyatigorsk State Research Institute of Balneotherapeutics
Pyatigorsk State Pharmaceutical Academy